Publications by authors named "Ya-qiong Zhou"
Background: The neutrophil to lymphocyte ratio (NLR) has been reported as a novel predictor for atherosclerosis and cardiovascular outcomes. This study aimed to determine the effects of NLR on long-term clinical outcomes of chronic total occlusion (CTO) patients.
Methods: A total of 670 patients with CTO who met the inclusion criteria were included at the end of the follow-up period.
Article Synopsis
- * Researchers are prioritizing the discovery of alternative antigens specific to MM, with GPRC5D emerging as a key target since it is predominantly expressed in MM plasma cells and minimally in normal tissues.
- * A new bispecific antibody, BR109, has been developed to target both GPRC5D and CD3, demonstrating strong T-cell-mediated cytotoxicity against MM cells and effective antitumor activity in preclinical models, setting the stage for future clinical trials.
Objective: To determine the role of Tripterygium wilfordii multiglycoside (TGW) in the treatment of psoriatic dermatitis from a cellular immunological perspective.
Methods: Mouse models of psoriatic dermatitis were established by imiquimod (IMQ). Twelve male BALB/c mice were assigned to IMQ or IMQTGW groups according to a random number table.
Article Synopsis
- Neutralizing monoclonal antibodies (nMABs) are effective in treating COVID-19, and researchers developed a new version called 55,315-VLVH to increase its potency.
- This new tetravalent IgG1-(scFv) construct combines two single chain variable fragments (scFv) with the original nMAB, improving its binding activity against spike protein variants and enhancing neutralization against variants of concern (VOCs).
- While the new version shows better antibody-dependent cellular phagocytosis (ADCP) without increasing inflammatory responses, it may lead to higher systemic inflammation through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), requiring further research
Article Synopsis
- Immune checkpoint inhibitors (ICIs) show promise in cancer treatment, but many patients still struggle to achieve long-term benefits due to factors like TGF-β promoting cancer progression and resistance to these therapies.
- Researchers developed a bifunctional protein called BR102 that combines anti-PD-L1 antibodies and TGF-βRII, allowing it to target both PD-L1 and TGF-β simultaneously without losing blocking capability.
- Preclinical tests indicate that BR102 effectively inhibits tumor growth and is well-tolerated in monkeys, suggesting it could be a promising avenue for improving cancer treatment through enhanced ICI effectiveness.
Background: Biological agents have been used with extreme caution in children because of their possible adverse effects.
Objectives: This study used high-quality randomized controlled trials (RCTs) to provide high-level evidence to assess the effectiveness and safety of biological agents for treating children with psoriasis.
Methods: We searched PubMed, Embase, Cochrane, and Web of Science databases through October 31, 2021.
Traditional Chinese medicine is effective in the treatment of psoriasis and can significantly reduce skin inflammation and psoriatic lesions with minimal side effects. Shikonin (SHI) and β,β-dimethylacryloyl alkannin (DMA), the main active components of , have strong anti-inflammatory effects. This systematic review aimed to evaluate the efficacy and safety of and its main active components and to elucidate the potential mechanisms of their action in psoriasis treatment.
View Article and Find Full Text PDFBackground: Psoriasis is an autoimmune disease mediated by T cells. However, treatment remains a clinical challenge because of its frequent recurrence. Celastrol (Cel), the main active ingredient in Tripterygium wilfordii Hook F, is efficacious in treating autoimmune diseases such as psoriasis.
View Article and Find Full Text PDFBackground: Psoriasis is an autoimmune skin disease associated with lipid metabolism. Sphingosine-1-phosphate (S1P) is a bioactive lipid that plays a key role in the development of autoimmune diseases. However, there is currently a lack of comprehensive evidence of the effectiveness of S1P on psoriasis.
View Article and Find Full Text PDFThe novel anti-PD-L1/TGFBR2-ECD fusion protein (BR102) comprises an anti-PD-L1 antibody (HS636) which is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment. In the expression of TGFBR2-ECD wild-type fused protein (BR102-WT), a 50 kDa clipped species was confirmed to be induced by proteolytic cleavage at a "QKS" site located in the N-terminus of the ectodomain, which resulted in the formation of IgG-like clipping. The matrix metalloproteinase-9 was determined to be associated with BR102-WT digestion.
View Article and Find Full Text PDFArticle Synopsis
- Psoriasis and dementia were investigated for potential associations in a study due to conflicting existing evidence regarding inflammatory diseases.
- The analysis included nine studies with over 3.6 million participants, revealing that patients with psoriasis have a higher risk of various types of dementia compared to those without.
- No significant reasons for variability were found, suggesting that while dementia is linked to psoriasis, it may not escalate mortality rates associated with severe psoriasis; early identification of these risks could help manage health outcomes.
Bispecific antibodies have been exploited as both cancer immunodiagnostics and cancer therapeutics, which have shown promises in clinical trials in cancer imaging and therapy. To improve the anti-tumor effect, an scDb (bispecific single-chain diabody) was constructed from the variable domain genes of two scFvs (single-chain variable fragment antibodies) directed against human EGFR (epidermal growth factor receptor) and VEGFR2 (vascular endothelial growth factor receptor 2) extracellular domains. The anti-EGFR/ anti-KDR scDb was constructed into pHEN2 plasmid and expressed in Escherichia coli HB2151 host.
View Article and Find Full Text PDF